Vanderbilt University Medical Center: Study Shows Better Option for Treatment of Inoperable Anal Cancer
June 25, 2020
June 25, 2020
NASHVILLE, Tennessee, June 25 -- Vanderbilt University Medical Center issued the following news:
People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
The results from an international trial, published by the Journal of Clinical Oncology,suggest that carboplatin-paclitaxel become the standard of care for anal cancer, a rare diseas . . .
People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
The results from an international trial, published by the Journal of Clinical Oncology,suggest that carboplatin-paclitaxel become the standard of care for anal cancer, a rare diseas . . .